Diuretic
ApprovedSmall molecule
Diuretic is one of 78 small molecule programs targeting Cardiomyopathy. It is currently in Approved.
5
Indications
7
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Diuretic
RReprieve Cardiovascular, Inc
Approved
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Refractory1 trial
Breast Cancer1 trial
Long-term Use of CCB and Breast Cancer Risk
Active, not recruiting·—··NCT05972785·68,500 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diuretic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RReprieve Cardiovascular, Inc